NASDAQ · OMER
Healthcare · Biotechnology
$18.61
Up+$0.14 (+0.76%)
Updated Oct 4, 2026, 6:54 PM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · OMER
1M range · 0 trading sessions · Daily adjusted prices
OMER does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning OMER.
Company
Market Activity
Research & News
OMER research
Company profile and research snapshot.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 22, 2026 | Cantor Fitzgerald | Overweight | — |
| Jun 26, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 10, 2026 | HC Wainwright & Co. | Buy | — |
| May 14, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 21, 2026 | D. Boral Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Feb 17, 2026
Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates evaluating the efficacy and safety of its OncotoX-AML cancer therapeutic platform. Omeros' OncotoX-AML
Yahoo · Jan 27, 2026
SEATTLE, January 27, 2026--Omeros Corporation (NASDAQ: OMER) today announced that the first commercial shipments of YARTEMLEA® (narsoplimab-wuug) to its distributors were completed last week, with orders from transplant centers beginning that same day. Both adult and pediatric patients with stem cell transplant-associated thrombotic microangiopathy (TA-TMA) are now receiving YARTEMLEA, including patients who have recently failed prior off-label C5-inhibitor regimens, in both hospital and outpati
Yahoo · Jan 20, 2026
Key market opportunities in Q1 2026 include significant regulatory catalysts like approvals for GSK's depemokimab, Regenxbio's gene therapy, and Omeros' narsoplimab. Ongoing trials by Xenon, Cerevel, and Neumora present additional potential. Focus areas include asthma, Parkinson's, MDD, and rare diseases.Dublin, Jan. 20, 2026 (GLOBE NEWSWIRE) -- The "Catalyst Monitor: Q1 2026 Outlook" report has been added to ResearchAndMarkets.com's offering.This report compiles published, predictive intelligen
SeekingAlpha · Jan 7, 2026
Omeros Corporation (OMER) Discusses FDA Approval and Commercialization Plans for YARTEMLEA in TA-TMA Treatment January 7, 2026 4:30 PM ESTCompany...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning OMER.
